Successful secondary prophylaxis for primary effusion lymphoma with human herpesvirus 8 therapy [6]

AIDS

Volumn 20, Issue 11, 2006, Pages 1567-1569

  Crum Cianflone, Nancy F ^a,b   Wallace, Mark R ^a   Looney, David ^c,d  

^a NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^b Tri Service AIDS Clinical Consortium   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; CIDOFOVIR; VALGANCICLOVIR; VIRUS ANTIBODY;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; CANCER CHEMOTHERAPY; CANCER PREVENTION; CASE REPORT; DISEASE DURATION; DRUG TREATMENT FAILURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MALE; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; SECONDARY PREVENTION; SURVIVAL TIME; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 8, HUMAN; HUMANS; LYMPHOMA, AIDS-RELATED; MALE; VIRAL LOAD;

EID: 33746211634     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000237381.92303.61     Document Type: Letter

References (9)

1. Knowles DM, Inghirami G, Ubriaco A, Dalla-Favera R. Molecular genetic analysis of three AIDS-associated neoplasms of uncertain lineage demonstrates their B-cell derivation and the possible pathogenetic role of the Epstein-Barr virus. Blood 1989; 73:792-799.
2. Simonelli C, Spina M, Cinelli R, Talamini R, Tedeschi R, Gloghini A, et al. Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study. J Clin Oncol 2003; 21:3948-3954.
3. Dupont C, Vasseur E, Beauchet A, Aegerter P, Berthe H, de Truchis P, et al. Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. AIDS 2000; 14:987-993.
4. Hocqueloux L, Agbalika F, Oksenhendler E, Molina J-M. Long-term remission of an AIDS-related primary effusion lymphoma with antiviral therapy. AIDS 2001; 15:280-281.
5. Spina M, Gaidano G, Carbone A, Capello D, Tirelli U. Highly active antiretroviral therapy in human herpesvirus-8-related body-cavity-based lymphoma. AIDS 1998; 12:955-956.
6. Neyts J, De Clercq E. Antiviral drug susceptibility of human herpesvirus 8. Antimicrob Agents Chemother 1997; 41:2754-2756.
7. Luppi M, Trovato R, Barozzi P, Vallisa D, Rossi G, Re A, et al. Treatment of herpesvirus associated primary effusion lymphoma with intracavitary cidofovir. Leukemia 2005; 19:473-476.
8. Klass CM, Offermann MK. Targeting human herpesvirus-8 for treatment of Kaposi's sarcoma and primary effusion lymphoma. Curr Opin Oncol 2005; 17:447-455.
9. Lehrman G, Hogue IB, Palmer S, Jennings C, Spina CA, Wiegand A, et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 2005; 366:549-555.